MammaPrint® – added value of using the gene expression signature test MammaPrint® for adjuvant chemotherapy decision-making in early breast cancer

National Health Care Institute (ZIN)
Record ID 32018001156
English
Authors' objectives: This is the assessment of the relative effectiveness of MammaPrint® – Added value of using the gene expression signature test MammaPrint® for adjuvant chemotherapy decision-making in early breast cancer
Details
Project Status: Completed
URL for project: https://eunethta.eu/final-assessment-report-on-mammaprint-added-value-of-using-the-gene-expression-signature-test-mammaprint-for-adjuvant-chemotherapy-decision-making-in-early-breast-cancer/
Year Published: 2018
URL for published report: https://eunethta.eu/final-assessment-report-on-mammaprint-added-value-of-using-the-gene-expression-signature-test-mammaprint-for-adjuvant-chemotherapy-decision-making-in-early-breast-cancer/
Requestor: HTA agencies
English language abstract: An English language summary is available
Publication Type: Rapid Review
MeSH Terms
  • Breast Neoplasms
  • Genes, Neoplasm
  • Genetic Testing
  • Prognosis
  • Chemotherapy, Adjuvant
  • Gene Expression Profiling
  • Gene Expression
Contact
Organisation Name: European Network for Health Technology Assessment
Contact Email: eunethta@zinl.nl
Copyright: CC-BY-NC: You may copy, distribute, display, perform, and modify and use the EUnetHTA work for any purpose other than commercially unless you get your permission first.
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.